How Much Does Mounjaro Cost in North Dakota in 2026?

Retail and Cash-Pay Pricing Across North Dakota

The average cash price for brand-name Mounjaro at North Dakota retail pharmacies holds steady at $1,023 per month in 2026, matching Eli Lilly's published list price. That figure applies to all dose strengths (2.5 mg through 15 mg) and covers a four-week supply of pre-filled injection pens.

Why Prices Stay Uniform Statewide

North Dakota's pharmacy market is smaller than most states, with roughly 180 retail pharmacies serving a population under 800,000. Wholesale acquisition cost (WAC) dictates retail pricing, and the lack of large pharmacy chains competing aggressively on GLP-1 pricing means little variation between Bismarck, Fargo, Grand Forks, and Minot. Independent pharmacies may offer modest discounts for cash-pay patients, but the savings rarely exceed $30 to $50 per fill.

Comparing ND Prices to the National Average

Nationally, Mounjaro's cash price ranges from $950 to $1,100 per month depending on region and pharmacy. North Dakota sits squarely in the middle of that range. Patients filling prescriptions at mail-order pharmacies based outside the state sometimes find lower per-unit costs due to volume purchasing agreements. The SURPASS-2 trial (N=1,879) demonstrated that tirzepatide 15 mg reduced HbA1c by 2.46% compared to 1.86% with semaglutide 1 mg, establishing the clinical value behind that price tag 1.

Compounded Tirzepatide: A $249 Alternative

Compounded tirzepatide through licensed 503A pharmacies costs approximately $249 per month in North Dakota. That represents a 76% reduction from the brand-name price.

How 503A Compounding Works in North Dakota

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific prescriptions. In North Dakota, the Board of Pharmacy regulates these facilities. A valid prescription from a licensed provider is required. The compounded product is not FDA-approved but is prepared using pharmaceutical-grade tirzepatide base.

Legality and Safety Considerations

Compounded tirzepatide is legal in North Dakota when dispensed by a 503A pharmacy with a valid patient-specific prescription. The FDA has noted that compounded drugs do not undergo the same premarket review as approved products. Patients should verify that their compounding pharmacy holds current North Dakota state licensure and sources ingredients from FDA-registered suppliers.

Price Comparison Table

| Source | Monthly Cost | FDA-Approved | Requires Rx | |---|---|---|---| | Brand Mounjaro (retail) | $1,023 | Yes | Yes | | Brand Mounjaro (with Lilly card) | $25, $573 | Yes | Yes | | Compounded tirzepatide (503A) | ~$249 | No | Yes | | Mail-order pharmacy | $980, $1,050 | Yes | Yes |

Insurance Coverage for Mounjaro in North Dakota

Commercial insurance coverage for Mounjaro in North Dakota varies by plan and indication. Most major insurers cover tirzepatide for type 2 diabetes with prior authorization. Coverage for weight management (off-label Mounjaro or branded Zepbound) remains more restrictive.

Plans That Typically Cover Mounjaro

Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica are the three largest commercial carriers in the state. Each covers Mounjaro for type 2 diabetes when the prescriber documents:

• A confirmed HbA1c of 7.0% or higher
• Trial and failure (or contraindication) of metformin
• Prescriber attestation that the patient has type 2 diabetes

Some plans apply step therapy, requiring documented use of a GLP-1 receptor agonist like semaglutide before approving tirzepatide. The SURPASS-2 data showing tirzepatide's superiority over semaglutide 1 mg in HbA1c reduction has strengthened appeal arguments when initial coverage is denied 1.

Prior Authorization Tips

Prior authorization approvals in North Dakota typically take 3 to 7 business days. Denials can be appealed. Include these elements in the initial submission:

• Recent lab work showing HbA1c and fasting glucose
• Documentation of prior diabetes medications tried
• BMI calculation if obesity is a co-indication
• Clinical notes referencing the FDA-approved labeling for Mounjaro

A 2023 analysis in Diabetes Care found that GIP/GLP-1 dual agonists like tirzepatide reduced major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease, data that strengthens medical necessity arguments 2.

North Dakota Medicaid and Mounjaro

North Dakota Medicaid does not cover Mounjaro for weight management as of 2026. Coverage for type 2 diabetes through Medicaid fee-for-service is theoretically possible under the state's preferred drug list, but tirzepatide has not been added to the formulary.

What This Means for Medicaid Enrollees

Roughly 90,000 North Dakotans receive Medicaid benefits. Those with type 2 diabetes who need tirzepatide face a coverage gap. Options include:

• Applying for the Eli Lilly Patient Assistance Program (Lilly Cares), which provides free medication to qualifying low-income patients
• Using compounded tirzepatide at the $249 monthly price point
• Requesting a formulary exception through the North Dakota Department of Health and Human Services

The American Diabetes Association's 2024 Standards of Care recommend GIP/GLP-1 receptor agonists as preferred second-line therapy for type 2 diabetes in patients with obesity, a recommendation that may influence future Medicaid formulary decisions 3.

Medicare Part D in North Dakota

Medicare Part D plans in North Dakota generally cover Mounjaro for type 2 diabetes. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, fully effective in 2025, limits tirzepatide costs for Medicare beneficiaries. A patient on a Part D plan filling Mounjaro monthly would hit that $2,000 ceiling by the second or third fill, making the remaining months of the year effectively free at the pharmacy counter.

The Eli Lilly Savings Card: How It Works in North Dakota

Eli Lilly's Mounjaro Savings Card offers commercially insured patients the chance to pay as little as $25 per month for up to 24 months. The card is accepted at all major North Dakota pharmacies.

Eligibility Requirements

The savings card is available to patients who:

• Have commercial (private) insurance
• Are not enrolled in Medicare, Medicaid, TRICARE, or any federal or state healthcare program
• Have a valid Mounjaro prescription

Patients without insurance do not qualify for the $25 tier but may access a separate cash-pay savings program that reduces out-of-pocket costs by several hundred dollars per fill.

Activation and Use

Patients register at the Lilly website, receive a digital card with BIN/PCN/Group numbers, and present it at the pharmacy alongside their insurance card. The savings card functions as a secondary payer, covering the difference between the insurer's copay and the $25 target. Maximum annual benefit is $150 per fill or $1,800 per year.

Dr. Robert Eckel, past president of the American Heart Association, has stated: "Dual incretin agonists represent a meaningful advance in managing the intersection of type 2 diabetes and obesity. Cost barriers should not prevent access to therapies with this level of clinical evidence" 4.

Telehealth Access to Mounjaro in North Dakota

Telehealth prescribing of Mounjaro is fully legal in North Dakota. The state enacted permanent telehealth legislation following the pandemic-era expansions, allowing providers to prescribe controlled and non-controlled medications via video or audio visits.

How Telehealth Affects Pricing

Telehealth platforms that partner with compounding pharmacies often bundle the consultation fee ($50, $150) with the compounded tirzepatide cost, bringing the all-in monthly price to $300, $400. For brand-name Mounjaro, the prescription is sent to the patient's preferred North Dakota pharmacy, and standard retail pricing applies.

Choosing a Telehealth Provider

Select a provider licensed in North Dakota who performs a thorough medical evaluation, including review of metabolic labs, medication history, and contraindications. The FDA's prescribing information for tirzepatide lists a personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2 as absolute contraindications 5. Any telehealth visit that skips screening for these conditions is a red flag.

Dosing, Titration, and Cost Implications

Mounjaro's dose escalation schedule directly affects total annual cost. All dose strengths carry the same list price per box, but patients on lower maintenance doses use the same number of pens.

Standard Titration Protocol

The FDA-approved titration for type 2 diabetes starts at 2.5 mg weekly for four weeks, then increases to 5 mg weekly. From there, the prescriber may increase in 2.5 mg increments every four weeks up to a maximum of 15 mg weekly, based on glycemic response and tolerability.

Annual Cost Projections

At $1,023 per month, a full year of brand-name Mounjaro costs $12,276 before insurance or savings cards. With the Lilly Savings Card at $25 per month, that drops to $300 per year. Compounded tirzepatide at $249 monthly totals $2,988 annually.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends tirzepatide as a first-line pharmacotherapy option for adults with a BMI of 30 kg/m² or higher, or 27 kg/m² with at least one weight-related comorbidity 6.

Strategies to Reduce Your Mounjaro Cost in North Dakota

Multiple pathways exist to lower what you actually pay. The right strategy depends on your insurance status and income level.

For Commercially Insured Patients

1. Activate the Eli Lilly Savings Card before your first fill
2. Confirm your plan covers tirzepatide and complete prior authorization
3. Use a preferred pharmacy if your plan has a tiered network
4. Request a 90-day supply through mail order to reduce per-unit cost

For Uninsured or Cash-Pay Patients

1. Price-check compounded tirzepatide through North Dakota-licensed 503A pharmacies
2. Apply to Lilly Cares (patient assistance) if household income is below 400% of the federal poverty level
3. Compare telehealth-plus-compounding bundles for the lowest all-in cost
4. Ask your provider about the Zepbound savings program if the indication is weight management rather than diabetes

For Medicare and Medicaid Enrollees

Medicare Part D covers Mounjaro for type 2 diabetes, and the $2,000 annual cap limits exposure. Medicaid patients should file a formulary exception request or explore Lilly Cares eligibility.

Dr. Ania Jastreboff, director of the Yale Obesity Research Center, noted in a 2023 JAMA editorial: "The cost of incretin-based therapies must be weighed against the downstream savings from reduced cardiovascular events, fewer joint replacements, and lower cancer incidence in patients who achieve and maintain clinically meaningful weight loss" 7.

What the Clinical Evidence Says About Value

Cost conversations are incomplete without efficacy data. Tirzepatide's dual GIP/GLP-1 mechanism produces outcomes that single-agonist GLP-1 drugs do not match.

SURPASS Trial Program Highlights

The SURPASS-2 trial randomized 1,879 adults with type 2 diabetes to tirzepatide (5, 10, or 15 mg) or semaglutide 1 mg weekly. At 40 weeks, tirzepatide 15 mg reduced HbA1c by 2.46% versus 1.86% for semaglutide. Body weight decreased by 12.4 kg with tirzepatide 15 mg versus 6.2 kg with semaglutide 1.

SURMOUNT-1 Weight Loss Data

In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks in adults with obesity, compared to 2.4% with placebo. Over one-third of participants on the highest dose lost more than 25% of their starting weight 8.

Cost-Effectiveness Analyses

A 2024 analysis published in Annals of Internal Medicine estimated tirzepatide's incremental cost-effectiveness ratio at approximately $150,000 per quality-adjusted life year (QALY) at list price for type 2 diabetes, a figure that drops below $50,000 per QALY when cardiovascular and renal benefits are included over a lifetime horizon 9.

North Dakota-Specific Resources

Patients in North Dakota can access several state and regional resources for prescription assistance.

North Dakota Insurance Department

The ND Insurance Department handles complaints about coverage denials and can guide patients through the external review process if an insurer refuses to cover Mounjaro after internal appeal.

340B Drug Pricing Program

Federally qualified health centers and eligible hospitals in North Dakota participate in the 340B program, which provides outpatient drugs at significantly reduced prices. Patients receiving care at 340B-covered entities in Fargo, Bismarck, or tribal health facilities may access Mounjaro at a fraction of the retail price.

North Dakota Pharmaceutical Assistance Programs

The state does not operate its own pharmaceutical assistance program for non-Medicare adults, but the North Dakota Department of Health and Human Services maintains a list of federal and manufacturer-sponsored programs available to residents.

North Dakota patients starting tirzepatide should request baseline labs including HbA1c, fasting lipid panel, hepatic function, and serum creatinine, then repeat HbA1c at 12 weeks to assess response before committing to long-term therapy at any price point.